Table A3.

Overview of self-report studies in older cancer survivors according to the systematic literature review.

Questionnnaires/Interviews
Freedman, 2013	PR	Breast	297 chemo	* 71.5	N.A.	NBF-ADL	-ChemoTx was not associated with longitudinal changes in self-reported cognitive function -No changes by Tx (standard vs capecitabine) -At 24 months, most survivors reported normal cognition
Heflin, 2005	CS	All (excluded brain)	702; 702 twin HC	N.A.	74.9	Telephone cognitive screening (unable or poor score on cognitive screening then BDRS); If score 3 Dementia screening using Diagnostic and Statistical Manual-IV criteria	-Long-term survivors presented higher rates of cognitive dysfunction complaints than their healthy twin -Cancer survivors were twice as likely to be diagnosed with dementia as their healthy twin
Hurria, Goldfarb, 2006	PR	Breast	45 chemo	70	N.A.	Squire Memory Self-Rating Questionnaire	-51% of survivors perceived decline in memory when comparing to before chemoTx
Keating, 2005	CS	All	964; 14 330 HC	55.0	68.3	Survey TICS	-Similar rates of self-reported memory, and among 65+, similar cognition scores between survivors and HC -No difference in cognitive complaints between survivors and HC
Mandelblatt, 2016	PR	Breast	519 chemo ± hormone 687 hormone alone	N.A.	72.7	EORTC-QLQ-C30	-Most older survivors maintained good long-term self-reported cognitive function (42%) -2.1x higher odds of accelerated decline when exposed to chemoTx (with or without anti-hormonal Tx) -Comorbidity (or frailty) and low pre-diagnosis function increased odds of accelerated cognitive decline -Age was not related to accelerated group -Cognition trajectories were related to physical function trajectories
Schilder, 2012	PR	Breast	80 Tamoxifen; 99 Exemestane; 120 HC	N.A.	68.7 Tamoxifen; 68.3 Exemestane; 66.2 HC	CFQ Dutch version; Interview questions “Do you have any complaints with regard to memory and attention/ concentration?” Neuropsychological tests Dutch Adult Reading Test; Fepsy Finger Tapping; Fepsy Reaction Times; RAVLT (immediate and delayed); SCWT; TMT A and B; VFT (phonetic, semantic); Visual Association Test; WAIS-III Letter-Number sequencing; WMS-R Visual Memory (immediate and delayed)	-Increased attention/concentration complaints in tamoxifen users 1 year after Tx, but not in exemestane -Tamoxifen or exemestane use did not influence self-reported frequency of cognitive failures -Self-reported cognitive function was associated with anxiety/depression, fatigue, and menopausal complaints -Cognitive test was not associated with self-reported cognitive functioning
Stava, 2006	CS	Breast; Other Female	814 breast cancer; - 334 chemo; - 470 no chemo 1894 other cancers	46.8 breast; 42.7 other	69.4 breast; 66.4 other	Survey	-Survivors who received chemoTx more frequently reported loss of memory (11.3% vs. 4.8%) -Women who received chemoTx more frequently reported loss of memory (12.3% vs. 7.2%) -Breast cancer survivors reported more loss of memory than other cancers (18.4% vs. 12.5%)

NOTE. * Indicates median. Abbreviations: 3MS, Modified Mini-Mental State Examination; AD, Alzheimer’s Disease; ADT, Androgen Deprivation Therapy; ApoE ε4, Apolipoprotein E; AVLT, Auditory Verbal Learning Test; BDRS, Blessed Dementia Rating Scale; BNT, Boston Naming Test; BVMT-R, Brief Visual-Memory Test-Revised; BVRT, Benton Visual Retention Test; CAMCO-G, Cambridge Cognitive Examination; CDR, Clinical Dementia Rating; CERAD-K-N, Consortium to Establish a Registry for Alzheimer’s Disease; CFQ, Cognitive Failure Questionnaire; CNS, Central Nervous System; COWAT, Controlled Oral Word Association Test; CRT, Complex reaction time; CS, Cross-sectional; CVLT, California Verbal Learning Test; D-KEFS, Delis-Kaplan Executive Function System; DSST, Digit Symbol Substitution Test; DTC, differentiated thyroid cancers; Dx, Diagnosis; EBPM, event-based prospective memory; EORTC-QLQ-C30, European Organization for Research and Treatment for Cancer Quality of Life Questionnaire; FAB-K, Frontal Assessment Battery; FACT-cog, Functional Assessment of Cancer Therapy-Cognitive Function; FDG, fluorodeoxyglucose; GMD, gray matter density; HC, healthy controls; H MRS, Proton Magnetic Resonance Spectroscopy; HVLT-R, Hopkins Verbal Learning Test, Revised; IED; Intradimensional/Extradimensional; IL-6, Interleukin 6; KDCT, Kendrick Assessment of Cognitive Aging battery; LDST, Letter-Digit Substitution Test; LHRH, Luteinizing hormone releasing hormone; LMWT, Luria Memory Word test; MDRS-2, Mattis Dementia Rating Scale-2; MFTC, Multiple Features Target Cancellation Test; MMSE, Mini-Mental State Exam; MoCA, Montreal Cognitive Assessment; MRI, Magnetic Resonance Imaging; MTCF, Modified Taylor Complex Figure Test; NAB, Neuropsychological Assessment Battery; NART, National Adult Reading Test; NBFADL, Neurobehavioral Functioning and Activities of Daily Living Scale; NHL, Non-Hodgkin Lymphoma; NMSC, Non-Melanoma Skin Cancer; No, number; PCI, prophylactic cranial irradiation; PET, Positron emission tomography; PMA-V, Primary Mental Abilities-Vocabulary; PPT, Purdue Pegboard Test; PR, Prospective; PTSD, Post-Traumatic Stress Disorder; RAVLT, Rey Auditory Verbal Learning Test; RCFT, Rey Complex Figure Test; ROCF, Rey–Osterrieth Complex Figure; RPM, Raven’s Progressive Matrices; RST, The Road Sign Test; RT, Radiotherapy; SCLC, Small Cell lung Cancer; SCWT, Stroop Color Word Test; SDMT, Symbol Digit Modalities Test; SRT, Simple reaction time; TBPM, time-based prospective memory; TIADL, Timed Instrumental Activities of Daily Living; TICS-m, Telephone interview cognitive screening; TMT, Trail Making Test; TSH, Thyroid Stimulating Hormone; Tx, Treatment; UFOV, Useful Field Of Vision; VFT, Verbal Fluency Test; WAIS-III, Wechsler Adult Intelligence Scale III; WASI, Wechsler Abbreviated Scale of Intelligence; WCST, Wisconsin Card Sorting Test; WFT, Word Fluency Test; WLT, 15-Word Learning Test; WMI, Working Memory Index; WMS, Wechsler Memory Scale; WRAT, Wide Range Achievement Test; Yrs, years.